Introduction: Fracture-related infections and implant-associated infections are major post-operative challenges encountered by orthopedic surgeons in their clinical practice. The occurrence of biofilm-forming bacteria on surgical implants is a serious problem that needs to be addressed post-surgically. Continuous local antibiotic perfusion (CLAP) using gentamicin (GM) for bone and soft tissue infections has been reported. This study aimed to elucidate the role of insulin-like growth factor 1 (IGF-1) in reducing the cytotoxicity associated with GM use in CLAP. In addition, we sought to assess the effectiveness of IGF-1 in facilitating the recovery of osteoblasts following CLAP treatment.
Methods: Osteoblasts were treated with 1,000, 2,500, or 5,000 μg/mL GM, and the changes in cell number; alkaline phosphatase (ALP) activity; and gene expression levels of collagen type 1, ALP, and RUNX2 were determined. These drug concentrations were used to simulate the concentrations used in clinical practice. After the 10-day GM treatment, the cells were treated with or without IGF-1, and the changes in cell number; ALP activity; and gene expression levels of collagen type 1, ALP, and RUNX2 were determined.
Results: GM treatment decreased the cell number, altered cell morphology, decreased ALP activity, and affected the expression of osteogenesis-related genes. Subsequent treatment with IGF-1 attenuated the GM-induced effects in the osteoblasts and partially recovered the cell number, morphology, ALP activity, and the expression of osteogenesis-related genes in GM-damaged cells.
Conclusions: IGF-1 administration promoted the recovery of osteoblasts and attenuated GM-induced toxicity in osteoblasts.
抄録全体を表示